Aligos Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
ALGS$3.95-2.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
Balance Sheets
| December 31,2025 | December 31,2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $18,303 | $36,997 |
| Restricted cash | 110 | 110 |
| Short-term investments | 59,541 | 19,942 |
| Other current assets | 4,908 | 5,092 |
| Total current assets | 82,862 | 62,141 |
| Operating lease right-of-use assets | 3,089 | 4,964 |
| Property and equipment, net | 1,867 | 2,362 |
| Other assets | 715 | 627 |
| Total assets | $88,533 | $70,094 |
| LIABILITIES AND | ||
| STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Current liabilities: | ||
| Accounts payable | $3,982 | $2,571 |
| Accrued liabilities | 13,526 | 15,557 |
| Operating lease liabilities, current | 3,580 | 3,422 |
| Finance lease liabilities, current | 145 | 36 |
| Deferred revenue, current | - | 151 |
| Total current liabilities | 21,233 | 21,737 |
| Operating lease liabilities, net of current portion | 1,525 | 4,795 |
| Finance lease liabilities, net of current portion | - | 122 |
| 2023 Common Warrants liability | 12,183 | 72,367 |
| Long term liability | 47 | 46 |
| Total liabilities | 34,988 | 99,067 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity (deficit): | ||
| Preferred Stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; no shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively. | - | - |
| Common stock, $0.0001 par value; 115,800,000 shares and 20,800,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 6,178,230 and 3,864,436 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively. | 9 | 8 |
| Additional paid-in capital | 695,269 | 588,576 |
| Accumulated deficit | (642,201) | (618,008) |
| Accumulated other comprehensive income | 468 | 451 |
| Total stockholders’ equity (deficit) | 53,545 | (28,973) |
| Total liabilities and stockholders’ equity (deficit) | $88,533 | $70,094 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.